Adbry (tralokinumab-ldrm) Injection 300 mg/2mL
LEO Pharma is recalling Adbry injection autoinjectors (NDC 50222-350-91, 50222-350-02) due to wool fiber contamination affecting sterility.
Do not use affected units. Contact LEO Pharma Inc. or your healthcare provider immediately if you have received or used this product. Return the autoinjector to your pharmacy or healthcare provider.
Why it was recalled
Lack of Assurance of Sterility: due to the presence of particulate matter in one unit from the lot, which lab tests have identified as wool fiber.
How to identify it
Adbry, (tralokinumab-ldrm) injection, 300 mg/2mL, Packaged as a) 1 x Single dose Autoinjector, SAMPLE NOT FOR SALE, NDC 50222-350-91; b) 2 x Single dose Autoinjectors, NDC 50222-350-02; Rx only, Manufactured by: LEO Pharma A/S. Industriparken 55, DK-2750 Ballerup, Denmark, Distributed by: LEO…
Where it was sold
Distributed in US.
Official source
Editorial summary by Recall Canary · last updated 2026-04-27 · primary source: U.S. Food and Drug Administration · severity reflects the agency's published classification